ImmuneAge Bio operates a drug discovery platform focused on immune system rejuvenation. The company utilizes its StemSupply platform to achieve over 1000x expansion of hematopoietic stem cells (HSCs). This technology supports both enhanced bone marrow transplants and high-throughput drug screening via the AgeScreen geroscience engine.
Funding
$12M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for expanding hematopoietic stem cells (HSCs) are limited, hindering high-throughput drug screening and development of effective therapies for immune system rejuvenation. This limitation slows the progress of discovering new treatments to enhance resilience against infections, cancer, and age-related immune decline.
Solution
ImmuneAGE Bio has developed the StemSupply platform, a novel method for achieving over 1,000x expansion of HSCs, enabling high-throughput drug screening on human HSCs for the first time. This platform facilitates the discovery of new molecules that regulate cellular aging and immune cell aging. By rejuvenating HSCs from the bone marrow, ImmuneAGE aims to enhance the body's ability to fight infections and cancer, ultimately improving healthspan and reducing hospital stays. The company's AgeScreen platform further supports geroscience drug discovery by identifying molecules that regulate cellular aging.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and clinicians focused on developing therapies for immune system rejuvenation, bone marrow transplantation, and age-related immune decline.
Features
- StemSupply Platform: Enables >1,000x expansion of hematopoietic stem cells (HSCs).
- AgeScreen: Geroscience drug discovery engine for identifying molecules regulating cellular and immune cell aging.
- High-throughput drug screening on human HSCs.
- Identification of new molecules to regulate cellular aging.